Literature DB >> 11731878

Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy.

D Testa1, D Monza, M Ferrarini, P Soliveri, F Girotti, G Filippini.   

Abstract

In order to identify early clinical features and survival predictors of supranuclear palsy (PSP) and multiple system atrophy (MSA), we compared the disease course of patients consecutively referred between 1987 and 1999 and followed to December 1999. Thirty-nine PSP and 74 MSA patients were diagnosed according to commonly accepted clinical criteria. Length of survival was ascertained from death certificates or by contacting relatives. Ten-year survival after disease onset was 29% for both disorders. Median survival was 7.0 years (PSP) and 7.5 (MSA). Neither age, symptoms at onset, or disability at diagnosis predicted survival. At diagnosis, all PSP patients had oculomotor palsy, whereas 89% of MSA patients had dysautonomia; bradykinesia and falls were the most frequent common signs. Distinctive early signs were palilalia, cognitive impairment and hyperreflexia in PSP; hypophonia, anterocollis and dysautonomia in MSA. MSA patients responded better to levodopa. Attention to early distinctive features can improve differential diagnosis and inform subsequent management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11731878     DOI: 10.1007/s100720100021

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  21 in total

1.  PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

Authors:  Georg Nuebling; Mira Hensler; Sabine Paul; Andreas Zwergal; Alexander Crispin; Stefan Lorenzl
Journal:  J Neurol       Date:  2016-05-26       Impact factor: 4.849

2.  [Progressive supranuclear palsy: living environment of the patients in Germany].

Authors:  M Hensler; S Paul; C Abright; S Lorenzl
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

3.  Normative Data for Brainstem Structures, the Midbrain-to-Pons Ratio, and the Magnetic Resonance Parkinsonism Index.

Authors:  S T Ruiz; R V Bakklund; A K Håberg; E M Berntsen
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-07       Impact factor: 3.825

Review 4.  Diagnosis of multiple system atrophy.

Authors:  Jose-Alberto Palma; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  Auton Neurosci       Date:  2017-10-23       Impact factor: 3.145

5.  Progressive supranuclear palsy: progression and survival.

Authors:  Julieta E Arena; Stephen D Weigand; Jennifer L Whitwell; Anhar Hassan; Scott D Eggers; Günter U Höglinger; Irene Litvan; Keith A Josephs
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

6.  Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.

Authors:  Milica Jecmenica-Lukic; Igor N Petrovic; Tatjana Pekmezovic; Vladimir S Kostic
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

7.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

8.  Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy.

Authors:  Heather M Clark; Rene L Utianski; Farwa Ali; Hugo Botha; Jennifer L Whitwell; Keith A Josephs
Journal:  Am J Speech Lang Pathol       Date:  2021-03-09       Impact factor: 2.408

Review 9.  Language impairment in progressive supranuclear palsy and corticobasal syndrome.

Authors:  Katie A Peterson; Karalyn Patterson; James B Rowe
Journal:  J Neurol       Date:  2019-07-18       Impact factor: 4.849

Review 10.  The role of the medial prefrontal cortex in cognition, ageing and dementia.

Authors:  Dan D Jobson; Yoshiki Hase; Andrew N Clarkson; Rajesh N Kalaria
Journal:  Brain Commun       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.